Gyre Therapeutics GYRE
NASDAQ GYRE
$6.86 +0.42 (+6.52%)
At close: Sep 4, 2026 · 4:00 PM EDT

Gyre Therapeutics (GYRE) EV to EBITDA (2010 - 2026)

Analysis

Gyre Therapeutics (GYRE) EV to EBITDA (2010 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Gyre Therapeutics 691.38 Mn 633.98 Mn 26.90 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -47.06
Mar 31, 2026 -66.54
Dec 31, 2025 4,890.96
Sep 30, 2025 94.37
Jun 30, 2025 -290.43
Mar 31, 2025 300.41
Dec 31, 2024 1,582.99
Sep 30, 2024 256.49
Jun 30, 2024 321.97
Mar 31, 2024 184.36
Dec 31, 2023 -21.43
Sep 30, 2023 0.89
Jun 30, 2023 0.35
Mar 31, 2023 -0.71
Dec 31, 2022 -1.09
Sep 30, 2022 1.42
Jun 30, 2022 -0.38
Mar 31, 2022 0.96
Dec 31, 2021 1.02
Sep 30, 2021 -2.34